# Legal Review — KANTIPUR VET DISTRIBUTORS PVT. LTD. (Nepal)

*Advisory analysis only. Not a substitute for licensed Indonesian / Nepali legal counsel — review with internal legal before signing or acting.*

**Counterparty:** KANTIPUR VET DISTRIBUTORS PVT. LTD., Nepal
**JAPFA principal:** PT Vaksindo Satwa Nusantara (Indonesian exporter)
**Agreement type:** Distributorship Agreement (signed 25-03-2024 by Anish Badal, Executive Director)
**Effective Date:** 1 January 2024
**Stated termination date:** 1 January 2027 (3-year term)
**Status today (14 May 2026):** **LIVE — ~7.5 months remaining**
**Future-dated draft:** "Agreement-Kantipur ED 1 Jan 2027.pdf" — **UNSIGNED renewal template** (placeholder, not an executed second contract)
**Operational LoA:** Dated 16 January 2026, lists 10 SKUs, terminates earlier LoA — **CURRENT and aligned with the live agreement**
**Governing law:** Republic of Indonesia
**Dispute resolution:** SIAC Singapore (Art. 35.2) — **clean single-forum clause**

---

## Executive summary — what this contract really is

This is the **second Nepal Vaksindo distribution agreement**, signed roughly 12 months after Agri Nutrition. It uses the same JAPFA / Vaksindo template but with **three material improvements** over Agri Nutrition:

1. **Dispute clause is CLEAN** — single SIAC Singapore (Art. 35.2). No BANI dual-track. This is the JAPFA-favorable benchmark clause. (Agri Nutrition Art. 34.2 was broken.)
2. **Initial Period → Exclusive Conversion mechanic** — Art. 2.1 says appointment is non-exclusive in the Initial Period (1 Jan 2024 – 31 Dec 2024), then **converts to exclusive on 1 January 2025 conditional on Distributor meeting Schedule A targets**, subject to "formal review on 1st January 2025". Exclusivity then runs through 1 January 2027.
3. **3-year term cleanly defined** with automatic expiry on 1 Jan 2027 unless terminated earlier (Art. 23.1).

The commercial substance: 10 SKUs in Schedule A (Vaksimune ND LS, ND H120, ND Clone, ND Clone CIP, ND IB, ND B1 IB, IBD, IBD Mplus, IBplus, Vaksimune ND Multi IBPLUS, ND Lasota Inactif), with sales-volume targets across 1 Jan 2024 / 1 Jan 2025 / 1 Jan 2026, plus 20% upward revision built in. Pricing CIF Tribhuvan International Airport, Kathmandu (Art. 3.1). LC 45 days payment (Art. 9.1.2). MA registration held in distributor's name **as Vaksindo's bailee** (Art. 4.2) — strongest JAPFA-favorable clause.

**Three live issues need resolution this week:**

1. **The 1 January 2027 "future-dated agreement" is an UNSIGNED renewal placeholder** — same template structure, effective 1 Jan 2027, signatory names typed but signature blocks BLANK and no signed date. This is the renewal Vaksindo is **getting ready to execute** — it is NOT an additional concurrent contract. There is a minor drafting bug (the "Initial Period" inside this 2027 draft still ends 31 Dec 2024, copied from the 2024 original) that must be fixed before signing.
2. **Exclusivity conversion as of 1 January 2025 — STATUS UNCONFIRMED.** Did Kantipur hit 2024 Schedule A targets? If yes, Kantipur was exclusive from 1 Jan 2025 to today, which means **Vaksindo's continued supply to Agri Nutrition through Q1 2025 – present is a potential breach of Kantipur's exclusivity**. Pak Yusman must pull 2024 actuals immediately. **The 16 Jan 2026 LoA listing 10 SKUs is consistent with exclusive operation** — i.e., on its face Vaksindo is already behaving as if Kantipur is the exclusive Nepal distributor.
3. **Territory and product overlap with Agri Nutrition is real and material.** Both contracts cover "Nepal" (no sub-territory carve-out). Of Agri Nutrition's 8 Schedule A SKUs and Kantipur's 10 Schedule A SKUs, the overlap is significant: Vaksimune NDLS, ND Clone-family, IBD, IBD M+, IBplus, ND Lasota Inactif. Both contracts cover the same vaccines in the same country.

Liability cap 1 month of purchases (Art. 21.4) — same as Agri Nutrition, same -3. KUHPerdata Art. 1266/1267 waiver missing. Adverse-event reporting 10 days (Art. 13.6) — borderline.

**Verdict:** **Renew on improved terms.** **B-band score** — meaningfully stronger than Agri Nutrition due to the clean SIAC clause, but still carries the Kantipur-vs-Agri Nutrition conflict overhang and the 1-month liability cap. The 2027 renewal is the moment to fix the residual gaps and (critically) decide whether Vaksindo wants Kantipur as the **sole** Nepal distributor going forward.

---

## Score: 74 / 100 — Grade B

**Verdict:** acceptable — fix residual drafting (KUHPerdata waiver, MA transfer-back timeline, liability cap), resolve exclusivity-trigger fact pattern, then execute the 1 Jan 2027 renewal.
**Confidence:** High (full 16-page signed agreement readable; 16-page unsigned 2027 draft readable; 1-page LoA dated 16 Jan 2026 readable; cross-checked Agri Nutrition memo from 2026-05-14).

### Section breakdown

| # | Section | Score | Weight | Rationale |
|---|---------|-------|--------|-----------|
| 1 | Territory, exclusivity & multi-distributor permissibility | 7 / 12 | 12 | Territory = "Nepal" (Art. 1, Schedule A) — overlaps wholly with Agri Nutrition. **Exclusivity mechanic is well drafted** (Art. 2.1 — Initial Period non-exclusive → conversion to exclusive on 1 Jan 2025 conditional on Schedule A target achievement) (+3). **But** the exclusivity, if triggered, creates an immediate conflict with the still-live Agri Nutrition contract (-4). No carve-out language acknowledging Agri Nutrition. |
| 2 | Pricing, payment & FX | 8 / 10 | 10 | CIF Tribhuvan International Airport, Kathmandu (Art. 3.1); annual mutual price revision (Art. 3.2); LC 45-day at acceptable bank (Art. 9.1.2); TT option also offered (Art. 9.1.1). Solid commercial mechanics. No Nepal Rastra Bank 180-day repatriation reference — minor info-only gap. |
| 3 | Time-tiered discounts & rebates | 3 / 6 | 6 | Silent. No volume-tier discount mechanism. 20% upward annual revision (Schedule A) is the only escalator — works in JAPFA's favor. |
| 4 | Sales targets & minimums | 6 / 8 | 8 | Schedule A quantitative across 3 years (10 SKUs, volumes & values stated for 2024 / 2025 / 2026). Rolling Projection Schedule mechanism (Art. 18.2-18.4) — distributor must provide 3-month written forecast each quarter; annual forecast by 31 October. Art. 18.3 third-party-appointment lever if no forecast agreed by Oct 31 (+2). |
| 5 | Termination, post-term & counterparty-country termination compensation | 7 / 14 | 14 | KUHPerdata Art. 1266/1267 waiver missing (-3). 6-month sell-off period (Art. 24.2) — half of Agri Nutrition's 12 months, still workable. MA transfer-back (Art. 24.3-24.5) solid. No specific transfer-back deadline. Nepal: no agency-law mandatory compensation per country notes — clean. |
| 6 | Registration / MA / NIE ownership & practical recoverability | 9 / 12 | 12 | Art. 4.2: "registration shall be at all times owned by Supplier, even if held in name of Distributor" — distributor is **bailee** ("trustee") to Supplier (+3). Art. 4.5: free-of-cost transfer at termination. Art. 24.3-24.5: distributor must apply to Regulatory Authorities to withdraw registration. Strong language. **One weak point**: no specific deadline (e.g., 30 days) for the DDA Nepal transfer-back process. |
| 7 | International dispute & enforceability in counterparty country | 11 / 14 | 14 | **CLEAN single SIAC Singapore clause** (Art. 35.2) (+8). 30-business-day good-faith negotiation precondition (Art. 35.1) — workable. Nepal is NY Convention signatory (acceded 1998) — SIAC award enforceable through Patan High Court commercial bench. Indonesian governing law preserved (Art. 35.1). **Minus**: no language-of-arbitration specified (-2), no tribunal-size specified (-1). |
| 8 | IP, confidentiality & non-compete | 5 / 6 | 6 | Art. 6 Competing Products non-compete during term; Art. 10-11 trademark + IP licensing tight; Art. 16.6 5-year confidentiality survival post-termination (+1). |
| 9 | Liability, indemnity & compliance reps (sanctions/Bahasa excluded) | 5 / 8 | 8 | Art. 21.4: 1-month-of-purchases liability cap (-3 per rubric). Art. 21.1 distributor-side indemnification broad. Art. 21.3 consequential damages exclusion (clean). Art. 25 anti-bribery / no-forced-labor / no-child-labor language present. Sanctions reps missing: info-only per concern profile, no deduction. |
| 10 | Counterparty-country voidance risks & misc boilerplate | 7 / 10 | 10 | **Stamp Act 2019** may apply to commercial agreements — verify with Nepali counsel. Language: Nepali required for state-court evidence — English-only, fine for SIAC. Hague Apostille: Nepal is NOT a member — consular legalization for any cross-border evidence. NRB FX 180-day rule: not addressed. Force majeure (Art. 28) reasonable. |
| | **Total raw** | **68 / 100** | | |
| | **+ positives** | **+6** | | Indonesian governing law preserved +2; MA bailee construction +2; clean single SIAC Singapore clause (above benchmark) +3; explicit Initial-Period-to-exclusive conversion mechanic well-drafted +1; minus 2 for missing exclusivity carve-out for Agri Nutrition overlap |
| | **Final** | **74 / 100** | | **Grade B** |

### Score drivers

**Largest positive drivers**
- **Section 7 — Clean SIAC Singapore single-forum clause** (+8 vs benchmark): Art. 35.2 is exactly what JAPFA wants. No BANI fallback, no "or" trap, no parallel-forum stalemate risk. This is the benchmark clause the Agri Nutrition contract is missing.
- **Section 6 — MA bailee construction** (+3): Art. 4.2 keeps regulatory ownership with Vaksindo.
- **Section 1 — Exclusivity conversion mechanic well drafted** (+3): Conditional exclusivity tied to Schedule A target achievement, with explicit 1 Jan 2025 review date. Either party can audit performance and the trigger is objective.

**Largest negative drivers**
- **Section 1 — Territorial overlap with Agri Nutrition** (-4): Both contracts cover "Nepal", with overlapping Vaksimune SKUs. If exclusivity converted on 1 Jan 2025, Vaksindo is in latent breach of Kantipur every shipment to Agri Nutrition since then.
- **Section 5 — KUHPerdata 1266/1267 waiver missing** (-3): Same gap as Agri Nutrition; one-line fix at renewal.
- **Section 9 — 1-month liability cap** (-3 capped per rubric): Same aggressive cap as Agri Nutrition; small commercial cost to lift to 6-12 months.
- **Section 5 — MA transfer-back has no timeline** (-1): Open-ended cooperation duty is risky if relationship sours.

### Score trajectory if negotiated

- If JAPFA wins residual fixes at 1 Jan 2027 renewal (KUHPerdata waiver + 30-day MA transfer-back deadline + 12-month liability cap + arbitration language clarification): **~84 / 100 (Grade A-)**.
- If JAPFA accepts the current 2027 draft as-is (it's literally the same template): **74 / 100 (Grade B)** — same as today.

Traffic light: **AMBER-GREEN**.

---

## Resolutions of the three open questions

### (a) What is the 1 January 2027 future-dated agreement?

**Answer: It is an UNSIGNED renewal placeholder/template — NOT an executed concurrent contract.**

Evidence (page-15 of the 2027 file):
- Signatory names typed: Dr. Teguh Yodiantara Prajitno (President Director, Vaksindo) and Anish Badal (Executive Director, Kantipur).
- **Signature blocks are BLANK.** No ink, no Bikram Samvat signing date, no company seal/stamp.
- Body text is materially identical to the signed 2024 agreement, except:
  - Recitals/Art. 2.1 effective date changed to 1 January 2027.
  - Title block updated.
  - **Drafting bug**: Art. 2.1 of the 2027 draft still says the Initial Period ends "31st December 2024" with exclusivity conversion review "on 1 January 2025". This is copy-paste error from the 2024 original — should read 31 December 2027 (or appropriate post-2027 date). **Must be corrected before execution.**

**This is the document Vaksindo will sign on or before 1 January 2027 to extend the Kantipur relationship for another 3-year term to 1 January 2030.** It is NOT a concurrent second agreement. It does NOT create double-distributor exposure with the live agreement (because the live one expires 1 Jan 2027, the day this one takes effect — seamless rollover).

**Action: Treat the 2027 file as the renewal draft. Fix the Initial Period date bug. Add the negotiation moves listed in the "Top negotiation moves" table below before circulation for signature.**

### (b) Exclusivity conversion trigger 1 January 2025 — did Kantipur hit 2024 targets?

**Answer: UNKNOWN from the contract files alone. MUST be resolved by Pak Yusman this week from Vaksindo's internal sales records.**

What the contract says (Art. 2.1): *"The non-exclusive appointment shall commence on the effective date of this Agreement, being 1st January 2024, and shall last for a period of one year (the 'Initial Period'), concluding on 31st December 2024. Upon the successful achievement of the targets as set forth in Schedule A during the Initial Period, the Distributor's appointment shall automatically convert to an exclusive basis for the promotion, sale, and distribution of the Products specified in Schedule A in the Territory. This exclusivity shall commence immediately following the Initial Period and extend until the end of the Agreement on 1st January 2027. This exclusivity is conditional upon the Distributor achieving the specified targets in Schedule A during the Initial Period and is limited to the Products specified therein. The achievement of these targets and subsequent transition to exclusivity will be subject to a formal review on 1st January 2025."*

**Schedule A 2024 targets (1st year, Initial Period):**
| # | Product | Pack | Quantity | Value (USD) |
|---|---------|------|----------|-------------|
| 1 | Vaksimune ND LS | 1000 ds | 5,000 | 19,000 |
| 2 | Vaksimune ND Clone | 1000 ds | 5,000 | 19,000 |
| 3 | Vaksimune ND B1 | 1000 ds | 4,000 | 16,000 |
| 4 | Vaksimune ND CB | 1000 ds | 5,000 | 14,500 |
| 5 | Vaksimune ND Clone IB | 1000 ds | 7,200 | 27,000 |
| 6 | Vaksimune IB | 1000 ds | 5,000 | 17,500 |
| 7 | Vaksimune NDL Multi IBPLUS | 1000 ds | 6,000 | 27,000 |
| 8 | Vaksimune NDL Lasota Inactif | 250 ds | 1,800 | 41,400 |
| 9 | Vaksimune ND IB Lasota | 1000 ds | 4,200 | 13,650 |
| 10 | Vaksimune ND L Inaktif | 1000 ds | 9,500 | 95,000 |
| | **Total Year 1** | | | **~290,050** |

(Numbers read off the Schedule A scan — adjust against Vaksindo's source spreadsheet.)

**Strong circumstantial evidence Kantipur DID hit targets and exclusivity DID convert:**
1. The 16 Jan 2026 LoA lists 10 SKUs for Kantipur — broadly the same set as Schedule A — and **terminates the earlier LoA**. Behaviorally, Vaksindo is treating Kantipur as the operational Nepal partner.
2. The 1 Jan 2027 renewal template was already drafted with the same language, suggesting business continuity is intended.
3. No internal memo or written waiver has been produced revoking exclusivity.

**Conservative assumption: exclusivity DID convert on 1 Jan 2025.** Until proven otherwise:
- Continued supply to Agri Nutrition Jan 2025 – present is **latent breach of Kantipur's exclusivity** for the overlapping SKUs.
- Kantipur could, in principle, file a SIAC claim citing Art. 35.2 and demand damages for the period of dual supply. Damages likely measurable from Agri Nutrition's invoiced volumes Jan 2025 onward for overlapping SKUs.
- The Agri Nutrition contract has now EXPIRED (30 March 2026 per the Agri review memo). So the breach window — IF it exists — is **Jan 2025 to 30 March 2026 = ~15 months**.

**Action: Pak Yusman to pull Vaksindo Nepal sales by distributor for 2024. Document target achievement in writing this week. If exclusivity converted, do a quiet internal memo + decide whether to disclose to Kantipur or sit on it (Kantipur may not know about Agri Nutrition).**

### (c) Territory / product overlap with Agri Nutrition

**Answer: SIGNIFICANT and unmanaged. Both contracts cover the same territory (Nepal) and most of the same vaccines.**

**Territory overlap: 100%.** Both contracts define Territory = "Nepal" with no sub-territory carve-out (Kantipur Art. 1 / Schedule A; Agri Nutrition Art. 1.14).

**Product overlap (Schedule A vs Schedule A):**

| Product family | In Agri Nutrition Schedule A | In Kantipur Schedule A | OVERLAP? |
|---------------|------------------------------|------------------------|----------|
| Vaksimune ND LS | YES | YES | **YES** |
| Vaksimune ND Clone (variants) | YES | YES (3 variants) | **YES** |
| Vaksimune ND B1 | YES (likely) | YES | **YES** |
| Vaksimune IBD / IBD M+ | YES | YES (IBD, IBD Mplus) | **YES** |
| Vaksimune IBplus | YES | YES (IB / IBplus) | **YES** |
| Vaksimune NDL Multi IBPLUS | YES | YES | **YES** |
| Vaksimune ND Lasota Inactif | YES | YES | **YES** |
| Vaksimune ND L Inaktif | YES | YES | **YES** |
| Pox / Coryza LE | YES | NO | NO |

**Conservatively: 8 of ~10 SKUs overlap.**

**Risk if Kantipur exclusivity converted on 1 Jan 2025:**
- Vaksindo's 8 overlapping SKUs sold to Agri Nutrition between 1 Jan 2025 and 30 March 2026 = ~15 months of breach.
- Kantipur damages claim (if asserted): theoretically the lost-margin on Agri Nutrition's volumes for the same SKUs, or specific performance demanding cessation. Specific performance is moot now (Agri Nutrition contract expired), so it's a damages claim only.
- Quantum: a function of Agri Nutrition's invoiced volumes Jan 2025 – Mar 2026 × Kantipur's margin. Could be USD 30K – 150K range, depending on actuals.
- Liability cap (Art. 21.4) of "1 month of Distributor's purchases" works in Vaksindo's favor here — limits Kantipur's recovery to 1 month of their own purchases (a tiny number).

**Strategic options (for internal decision at the 1 Jan 2027 renewal):**

| Option | Description | Pros | Cons |
|--------|-------------|------|------|
| **A. Consolidate behind Kantipur** | Don't renew Agri Nutrition (already expired); fix the 2027 Kantipur draft; Kantipur becomes sole Nepal distributor 1 Jan 2027 forward | Clean, no overlap, contract terms are stronger | Single point of failure; lose Agri Nutrition's network |
| **B. Keep both, formalize non-exclusivity in BOTH contracts** | Renew Agri Nutrition with explicit carve-out; modify Kantipur 2027 to remove exclusivity conversion mechanic | Two channels, distribution coverage redundancy | Need to renegotiate Kantipur's exclusivity (they may resist); pricing pressure |
| **C. Geographic split** | Renew Agri Nutrition with Eastern Nepal sub-territory carve-out; Kantipur keeps Western + Central with exclusivity intact | Both partners happy, no overlap | Operationally complex; Nepal is small market and distributors may both want Kathmandu |
| **D. Product split** | Kantipur takes ND/IB/IBD vaccines exclusively; Agri Nutrition takes Pox/Coryza and other non-overlapping SKUs | Clear lanes | Limits Agri Nutrition's commercial upside; may not be acceptable to them |

**Recommendation: Option A (consolidate behind Kantipur)**, unless Pak Yusman / Dr. Teguh have a strong relationship reason to keep Agri Nutrition. Reasoning: Kantipur's contract is materially stronger (clean SIAC clause; well-drafted exclusivity mechanic; 6-month sell-off; same MA bailee structure). Agri Nutrition's contract is expired. The 1 Jan 2027 Kantipur renewal is the natural integration point.

---

## Critical risks — 3 numbered, with plain-language and what-to-do blocks

### 1. CRITICAL — Latent exclusivity-breach exposure from Agri Nutrition concurrent supply (Jan 2025 – March 2026)

**What the contract says:** Art. 2.1 — exclusivity converts on 1 January 2025 conditional on Schedule A target achievement during 2024 Initial Period.

**Plain English:** If Kantipur hit its 2024 targets — and behaviorally Vaksindo seems to think it did — then from 1 January 2025 onward, Kantipur held exclusive rights for the listed Schedule A products in Nepal. Every shipment Vaksindo sent to Agri Nutrition for the same products in that window is a breach of Kantipur's exclusivity. The breach window runs from 1 January 2025 (exclusivity conversion) to 30 March 2026 (Agri Nutrition contract expiry) — about 15 months. Damages exposure is limited by the 1-month liability cap in Kantipur's Art. 21.4 (which protects Vaksindo, not Kantipur). The real risk is not damages — it's that Kantipur learns about the dual supply, loses trust, and starts looking for a competitor product to substitute. Brand reputation > legal damages here.

**What you should do:**
- **Day 0–7 (this week):** Pak Yusman to pull internal 2024 Kantipur sales actuals vs Schedule A 2024 targets. Document target achievement in a one-page internal memo.
- **Day 7–14:** Internal decision — was target hit? If yes, was the "formal review on 1 January 2025" actually conducted? Any written record on the Vaksindo side?
- **Day 14–30:** If exclusivity converted: do NOT volunteer disclosure to Kantipur unless asked. Prepare a "non-breach" defence file: (i) Agri Nutrition contract pre-existed Kantipur (signed 31 March 2023 vs Kantipur 25 March 2024), (ii) Agri Nutrition contract is non-exclusive on its face, (iii) Agri Nutrition contract has now expired — so going forward there is no concurrent supply. Frame any future Kantipur communication as "the Agri Nutrition relationship has ended" rather than admitting to historical concurrent supply.
- **Day 30–60:** At 1 Jan 2027 renewal: add a clause acknowledging that the new exclusivity period starts fresh from 1 Jan 2027 with no claims on prior period. Form of release.

---

### 2. HIGH — 1 Jan 2027 renewal draft has a date bug AND retains all the same residual gaps as the 2024 original

**What the contract says:** The 2027 draft (Agreement-Kantipur ED 1 Jan 2027.pdf) Art. 2.1 reads — *"The non-exclusive appointment shall commence on the effective date of this Agreement, being 1st January 2024, and shall last for a period of one year (the 'Initial Period'), concluding on 31st December 2024."* But the agreement is effective 1 January 2027. The Initial Period clause was not updated.

**Plain English:** Whoever drafted the 2027 renewal template duplicated the 2024 original and changed the headline effective date but missed the embedded reference to "1st January 2024" and "31st December 2024" inside Art. 2.1. If this is signed as-is, the Initial Period reads as already over (since 31 Dec 2024 is in the past), which makes the exclusivity conversion fire immediately on day 1 — possibly unintentionally. **This is a drafting bug that must be fixed before signing.** Beyond the date bug, the 2027 draft inherits every defect of the 2024 original: missing KUHPerdata waiver, no MA transfer-back timeline, 1-month liability cap, no language-of-arbitration specified in Art. 35.2.

**What you should do:**
- **Day 0–14:** Legal to draft renewal v2 with the fixes listed in the negotiation table below. Specifically:
  - Fix Art. 2.1 dates: Initial Period 1 Jan 2027 – 31 Dec 2027; exclusivity conversion review 1 Jan 2028.
  - Add KUHPerdata 1266/1267 waiver.
  - Add MA transfer-back 30-day deadline.
  - Specify SIAC language (English) and tribunal (1 arbitrator).
  - Lift liability cap to 12 months.
  - Tighten adverse-event reporting to 5 days.
- **Day 14–60:** Circulate to Kantipur for review. Negotiate. Execute before 1 January 2027.
- **Day 60–90:** If renewal is not yet executed by 1 Jan 2027, send a holdover side-letter so the live agreement continues on monthly terms until renewal executes — DO NOT let the contract simply expire.

---

### 3. HIGH — Multi-distributor strategy decision is now overdue and the 1 Jan 2027 renewal forces the question

**What the contract says:** Kantipur Art. 2.1 (exclusivity conversion). Agri Nutrition Art. 5 (non-exclusive). No cross-reference between the two contracts.

**Plain English:** Vaksindo has been operating two parallel Nepal distributorships for two years without an explicit board-level decision about whether that is desirable. The Agri Nutrition contract has now expired. The Kantipur contract is going into its renewal window. This is the cleanest moment in years to make the strategic call: one distributor or two? If two, with what carve-out? If one, which one? The pricing and commercial leverage depend on this answer. Pak Yusman and Dr. Teguh need to decide this BEFORE drafting the 1 Jan 2027 renewal — not after.

**What you should do:**
- **Day 0–14:** Internal Nepal strategy meeting (Pak Yusman + Dr. Teguh + Vaksindo export desk + JAPFA Indonesia commercial). Decision matrix:
  - Volumes by distributor 2024 / 2025
  - Margin by distributor
  - Sub-territory coverage (did Agri serve any geography Kantipur didn't?)
  - Brand relationship strength on each side
  - Pricing leverage if consolidated
- **Day 14–30:** Decision documented in a one-pager.
- **Day 30 onward:** Renewal drafting follows the strategy — not the other way around.

---

## High-priority items (same template gaps as Agri Nutrition — fix at renewal)

### 4. HIGH — 1-month liability cap (Art. 21.4) — extreme low (same gap as Agri Nutrition)

**What the contract says:** *"Supplier's liability under this agreement or for the termination of this agreement will not, in any event, exceed the price actually paid by the Distributor to Supplier for any of its obligations hereunder during the one month period immediately preceding the occurrence of the breach or damage."*

**Plain English:** At Kantipur's Schedule A run rate, 1 month of purchases is roughly USD 20K – 25K. Vaccine quality failure damages on Nepali flocks could exceed USD 200K. Same fragility as Agri Nutrition — protects Vaksindo on paper, but creates relationship fragility because the distributor has effectively no recourse for supplier breach.

**What you should do:** At 1 Jan 2027 renewal, offer to move to 12 months of purchases. Compromise position: 6 months.

---

### 5. HIGH — KUHPerdata Art. 1266 / 1267 waiver missing (same gap as Agri Nutrition)

**What the contract says:** Nothing. Art. 23 covers termination grounds but doesn't reference KUHPerdata.

**Plain English:** Under Indonesian Civil Code Articles 1266-1267, unilateral termination of a reciprocal contract requires court permission unless expressly waived. Without the waiver, Kantipur could in principle challenge a Vaksindo-initiated termination as not yet effective until an Indonesian judge confirms it. In practice rarely litigated cross-border, but the waiver is free and standard.

**What you should do:** At 1 Jan 2027 renewal, add this single sentence as Art. 23.4: *"The Parties hereby waive the application of Article 1266 and Article 1267 of the Indonesian Civil Code (KUHPerdata) such that no prior court order or judgement shall be required to give effect to any termination or rescission of this Agreement undertaken in accordance with its terms."*

---

### 6. HIGH — MA transfer-back has no timeline (same gap as Agri Nutrition)

**What the contract says:** Art. 24.3 — Distributor "shall file an application before the Regulatory Authorities in the Territory to withdraw its name as the registration holder" + Art. 4.5 "Distributor shall surrender usage rights to Supplier without any cost".

**Plain English:** DDA Nepal MA transfer process is 60-90 days with cooperation, 6-12 months without. For a vaccine business losing 6-12 months of market access is the single biggest economic exposure at termination.

**What you should do:** At 1 Jan 2027 renewal, add to Art. 24.3: *"Distributor shall complete and submit all required DDA Nepal forms, dossier transfer letters, and authorisation withdrawals within 30 (thirty) calendar days of termination or expiry, and shall provide reasonable cooperation thereafter to facilitate Supplier's appointment of a successor distributor. Any delay attributable to Distributor's non-cooperation entitles Supplier to liquidated damages of USD [X] per calendar day, capped at USD [Y]."*

---

## Compliance — 4-question framework

### Q1: Is the contract valid and enforceable in Indonesia (the governing-law jurisdiction)?

**Yes, materially clean.** Indonesian governing law preserved (Art. 35.1). Contract in English — UU 24/2009 bilingual rule info-only for outbound Vaksindo. KUHPerdata 1266/1267 waiver missing (item 5 above) — same fix as Agri Nutrition. Bea Meterai stamp duty informational only. **Verdict: enforceable in Indonesia.**

### Q2: Is the contract enforceable in Nepal (where assets and the distributor sit)?

**Yes — and stronger than Agri Nutrition.** Nepal acceded to NY Convention 1958 on 4 June 1998 with reciprocity reservation. A clean SIAC Singapore arbitration award would be enforceable through Nepal's Arbitration Act 2055 (1999) at the Patan High Court commercial bench. **The Kantipur dispute clause is clean (Art. 35.2 SIAC only)** — unlike Agri Nutrition's broken dual-track. Stamp Act 2019 BS: verify with Nepali counsel whether Nepal-side stamping was completed. Nepali-language: not an issue as long as disputes route to SIAC. Hague Apostille: Nepal NOT a member — consular legalization for cross-border evidence. **Verdict: enforceable via SIAC. Strong.**

### Q3: Are there sanctions, anti-bribery, or counterparty integrity issues?

**No live exposure.** Sanctions reps missing is info-only per concern profile, no deduction. Nepal not under blanket sanctions. Art. 25 has clean anti-bribery, no-forced-labor, no-child-labor language. **Verdict: clean.**

### Q4: Are JAPFA's regulatory commitments operationally workable?

**Yes.** Indonesian GMP referenced (Art. 13.1). 12-month shelf life floor at delivery (Art. 13.1) — workable. QC certificate per shipment (Art. 13.1) — standard. Adverse event reporting 10 days (Art. 13.6) — borderline, rubric flags >5 days as -2. Pharmacovigilance (Art. 26): mentioned but not detailed — same gap as Agri Nutrition. **Verdict: operational; tighten adverse-event timing at renewal.**

---

## Compliance checklist — Nepal-specific

| Item | Status | Action |
|------|--------|--------|
| DDA Nepal vaccine registration (Department of Drug Administration, dda.gov.np) | Held in distributor's name as Vaksindo's bailee per Art. 4.2; LoA dated 16 Jan 2026 confirms 10 registrations | Verify renewal status of each SKU with DDA |
| Nepal Rastra Bank — 180-day FX repatriation rule | Not addressed in contract | Confirm Kantipur has remitted all 2025/2026 USD payments to Vaksindo within 180-day window |
| Nepal Stamp Act 2019 BS | Unknown if stamped Nepal-side | Ask Nepali counsel; same approach as Agri Nutrition |
| Nepal Contract Act 2056 (2000) — multi-distributor permissibility | No statutory ban on multiple distributors | Continue current strategy pending Day-30 decision |
| Hague Apostille | Nepal is NOT a member | Use consular legalization (Embassy of Nepal in Jakarta) if Nepali-court evidence is needed |
| NY Convention 1958 | Nepal acceded 4 June 1998 (with reciprocity reservation) | SIAC Singapore awards enforceable — dispute clause already clean |
| Pharmacovigilance — Nepal DDA reporting | Mentioned in Art. 26 but no detail | Add a side-letter specifying DDA pharmacovigilance reporting workflow |
| Tax — Nepal withholding on imports / royalty | Not addressed | Confirm with internal tax |

---

## Top negotiation moves (at 1 Jan 2027 renewal)

| # | Move | Negotiability | What to ask for | Fallback |
|---|------|---------------|-----------------|----------|
| 1 | Fix Art. 2.1 Initial Period dates | HIGH (drafting error, must fix) | Initial Period 1 Jan 2027 – 31 Dec 2027; review on 1 Jan 2028 | n/a — non-negotiable correction |
| 2 | Add KUHPerdata 1266/1267 waiver | HIGH | One sentence in Art. 23 | Frame as housekeeping; no commercial cost |
| 3 | Clarify SIAC clause: English language + 1 arbitrator | HIGH | One paragraph rewrite | n/a — institutional default if both party silent |
| 4 | MA transfer-back 30-day deadline + per-day LD | MEDIUM | 30 days + cap at USD 50K | Frame as protecting both sides |
| 5 | Lift liability cap from 1 month to 12 months of purchases | MEDIUM | 12-month cap | 6-month cap is acceptable compromise |
| 6 | Adverse event reporting tightened to 5 days | LOW | 5 calendar days | Stay at 10 if pushback |
| 7 | Multi-distributor / carve-out language | HIGH (strategic) | Explicit acknowledgement that Vaksindo may appoint a sub-territory or product-specific second distributor at its discretion (preserves optionality) | Drop if consolidating behind Kantipur |
| 8 | Release of prior-period claims | MEDIUM | "Parties release each other from any and all claims arising prior to 1 January 2027" | Mutual release; standard at renewal |
| 9 | Pharmacovigilance side-letter referencing DDA Nepal workflow | LOW | One-page side-letter | Defer to renewal cycle 2 |
| 10 | Lift sell-off period from 6 months to 12 months | LOW | 12-month sell-off | Stay at 6 |

---

## Obligations timeline — operational checklist

| Owner | Action | Deadline | Status |
|-------|--------|----------|--------|
| Pak Yusman (Vaksindo) | Pull Kantipur 2024 actuals vs Schedule A targets — did exclusivity convert? | Day 7 (by 21 May 2026) | Open |
| Pak Yusman + Dr. Teguh | Internal Nepal strategy decision: consolidate behind Kantipur, keep both, or split? | Day 14 (by 28 May 2026) | Open |
| Pak Yusman | Document target achievement / non-achievement in internal one-page memo | Day 14 (by 28 May 2026) | Open |
| Legal | Draft Kantipur 2027 renewal v2 with: corrected Initial Period dates, KUHPerdata waiver, MA transfer-back deadline, 12-month liability cap, SIAC language clarification | Day 30 (by 13 June 2026) | Open |
| Pak Yusman | Send renewal v2 to Kantipur (Anish Badal) | Day 45 (by 28 June 2026) | Open |
| Both parties | Negotiate + execute renewal + new LOA | By 1 Jan 2027 | Open |
| Pak Yusman | Confirm Nepal Rastra Bank 180-day repatriation compliance for 2025–2026 USD remittances | Day 30 (by 13 June 2026) | Open |
| Pak Yusman | Pharmacovigilance side-letter — DDA Nepal reporting workflow | Day 90 (by 12 August 2026) | Open |
| Pak Yusman | If renewal not executed by 1 Jan 2027 — issue interim/holdover side-letter to keep contract alive | 1 Jan 2027 | Future contingent |

---

## Internal consistency check

| Item | Status |
|------|--------|
| Definitions used consistently across the contract? | Yes |
| Cross-references match? | Yes — Art. 24.2 references Art. 22.2 which is insurance; standard cross-ref |
| Schedule A products consistent with LOA? | Yes — both list ~10 Vaksimune ND / IBD SKUs; LoA naming slightly different but commercially aligned |
| Sign-off block matches party names? | Yes |
| Effective Date populated? | Yes — 1 January 2024 |
| Signature dates populated? | Yes on signed agreement — Anish Badal signed 25-03-2024 (Bikram Samvat). Dr. Teguh date blank but signature present. |
| Page numbering complete? | Yes |
| Schedule A signed? | Yes |
| Notice clause addresses match parties' actual addresses? | Yes |

---

## Priority focus area coverage

| # | Focus area | Covered? |
|---|-----------|----------|
| 1 | Territory / location of distribution | Yes — Schedule A, "Nepal" |
| 2 | Exclusivity terms (and multi-distributor permissibility) | Yes — Art. 2.1 conditional exclusivity conversion mechanic |
| 3 | Pricing & price adjustment | Yes — Art. 3 + Schedule A |
| 4 | Termination mechanics + counterparty-country mandatory termination compensation | Yes — Art. 23 + 24; no Nepal statutory exposure |
| 5 | Sales targets / minimum purchase | Yes — Art. 18 + Schedule A |
| 6 | Registration / MA / NIE ownership + transfer-back | Yes — Art. 4 + 24.3-24.5; missing 30-day deadline |
| 7 | Time-tiered discounts and rebates | No — silent |
| 8 | International dispute resolution and governing law — including ENFORCEABILITY | YES — clean SIAC clause; benchmark JAPFA-favorable |
| 9 | Multi-distributor strategy — can JAPFA appoint a second distributor? | Operationally yes; legally exposed if exclusivity converted on 1 Jan 2025 |
| 10 | Counterparty-country voidance risks (language, stamping, registration, formalities, agency-law mandatories) | Partial — Nepal Stamp Act and Nepali-language requirement not addressed; DDA Nepal addressed |

---

## Comparison to Agri Nutrition (same-country sibling contract)

| Factor | Agri Nutrition | Kantipur | Winner |
|--------|----------------|----------|--------|
| Effective date | 31 March 2023 | 1 January 2024 | n/a |
| Term | 3 years (expired 30 March 2026) | 3 years (expires 1 Jan 2027) | Kantipur (live) |
| Status today | EXPIRED 45 days ago | LIVE, 7.5 months left | Kantipur |
| Dispute clause | BANI **or** SIAC (broken dual-track) | SIAC Singapore only (clean) | **Kantipur** |
| Exclusivity | Non-exclusive permanently | Non-exclusive → exclusive 1 Jan 2025 (conditional) | Depends on JAPFA strategy |
| Liability cap | 1 month | 1 month | Tie (both weak) |
| KUHPerdata waiver | Missing | Missing | Tie (both weak) |
| MA transfer-back deadline | None | None | Tie |
| Sell-off period | 12 months (Art. 24.2) | 6 months (Art. 24.2) | Agri Nutrition |
| Score | 64 / 100 (Grade C) | 74 / 100 (Grade B) | **Kantipur** |

---

## Disclaimer

Advisory analysis only. Not a substitute for licensed Indonesian / Nepali legal counsel — review with internal legal before signing or acting. Findings are based on the 16-page signed Distribution Agreement (effective 1 January 2024, signed 25-03-2024 BS), the 16-page unsigned 1 January 2027 renewal template, the 1-page Letter of Authorization dated 16 January 2026, and cross-reference to the Agri Nutrition Distribution Agreement legal review memo dated 14 May 2026. Country-specific positions verified against `references/counterparty-country-notes.md` Nepal section as of May 2026.